Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.57 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086501 | 0.90 | FGFR1 (0.65) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4011092 | 0.89 | FGFR1 (0.48) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL3940505 | 0.88 | FGFR1 (0.55) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL5103566 | 0.88 | FGFR1 (0.59) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL3934716 | 0.85 | NR3C2 (0.44) | FGFR1IGF1RKDRFGFR2NR3C2 | |
| SCHEMBL4015943 | 0.85 | FGFR1 (0.45) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4089841 | 0.85 | FGFR1 (0.54) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4011783 | 0.84 | FGFR1 (0.58) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL13844709 | 0.81 | FGFR1 (0.86) | FGFR1IGF1RKDRINSRFGFR2 | |
| Hydrochloric Acid SCHEMBL4106603 | 0.80 | FGFR1 (0.85) | FGFR1IGF1RKDRINSRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | FGFR1 1428/4885IGF1R 3217/4885KDR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.